Predictive medicine: incipient reality or fata morgana?
Author:
Open Access
- 15 June 2007
- journal article
- review article
- Published by Wiley in The Journal of Pathology
- Vol. 212 (4) , 353-355
Abstract
The success of targeted therapy depends on reliable biomarkers that indicate the presence and accessibility of the target molecules with which the therapeutic drug will interact. In principle, this is independent of whether the drug is a small molecule, such as kinase inhibitors, or a therapeutic antibody, such as trastuzumab or cetuximab. The functional system of target–drug interaction is described as ‘predictive medicine’, one of the great hopes in the treatment of cancer. The major challenges are the precise prediction of the patient's individual prognosis, of the probability of metastases, and of individual therapeutic response. The questions, challenges, and possible answers related to this complex issue as well as the prerequisites for the development of more efficient and less toxic cancer therapy are discussed. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Genomic signatures to guide the use of chemotherapeuticsNature Medicine, 2006
- Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialNature Clinical Practice Oncology, 2006
- The US Food and Drug Administration perspective on cancer biomarker developmentNature Reviews Cancer, 2006
- Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A reviewVirchows Archiv, 2006
- Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survivalOncogene, 2005
- Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerThe Lancet, 2005
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Expression profiling predicts outcome in breast cancerBreast Cancer Research, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000